Drug interactions between Miradon and Terbinex with Eco Formula
| Results for the following 2 drugs: |
|---|
| Miradon (anisindione) |
| Terbinex with Eco Formula (hydroxypropyl chitosan/terbinafine topical) |
Interactions between your selected drugs
anisindione ↔ terbinafine
Applies to:Miradon (anisindione) and Terbinex with Eco Formula (hydroxypropyl chitosan/terbinafine topical)
MONITOR: The effect of terbinafine on oral anticoagulants, if any, is uncertain. A premarketing study conducted by the manufacturer demonstrated minimal alterations in the pharmacokinetics of a single dose of warfarin administered after 2 weeks of terbinafine compared to placebo. A postmarketing surveillance study of terbinafine in which 26 patients received concomitant treatment with warfarin also revealed no evidence of a drug interaction. However, there have been isolated case reports of INR changes (both increases and decreases) and gastrointestinal bleeding following the addition of terbinafine in patients stabilized on warfarin. A causal relationship has not been established, and the mechanism of the potential interaction is unknown. Terbinafine has not been shown to inhibit or induce CYP450 2C9 and 1A2, the predominant enzymatic pathways responsible for the metabolism of warfarin and similar anticoagulants.
MANAGEMENT: Until further data are available, it may be appropriate to monitor patients more closely during concomitant therapy. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of terbinafine in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
